Ren-Wang Peng

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 19

Top Topics

Combination Therapy

Epithelial Mesenchymal Transition

Reactive Oxygen Species

Top Venues

Cell death discovery

Journal of experimental & clinical cancer research : CR

Cancer research

This page only lists publications with an associated author ORCID identifier.

Publications

Xian Gong, Jianting Du, Ren-Wang Peng, Chun Chen, Zhang Yang
CRISPRing KRAS : A Winding Road with a Bright Future in Basic and Translational Cancer Research. Cancers 16 (2) (2024)
Xian Gong, Jianting Du, Ren-Wang Peng, Chun Chen, Zhang Yang
CRISPRing KRAS : A Winding Road with a Bright Future in Basic and Translational Cancer Research. Cancers 16 (2) (2024)
Haitang Yang, Yanyun Gao, Duo Xu, Ke Xu, Shun-Qing Liang, Zhang Yang, Amina Scherz, Sean R R Hall, Stefan Forster, Sabina A Berezowska, Feng Yao, Adrian F Ochsenbein, Thomas Michael Marti, Gregor Jan Kocher, Ralph A Schmid, Patrick Dorn, Ren-Wang Peng
MEK1 drives oncogenic signaling and interacts with PARP1 for genomic and metabolic homeostasis in malignant pleural mesothelioma. Cell death discovery 9 (1) (2023)
Haitang Yang, Yanyun Gao, Duo Xu, Ke Xu, Shun-Qing Liang, Zhang Yang, Amina Scherz, Sean R R Hall, Stefan Forster, Sabina A Berezowska, Feng Yao, Adrian F Ochsenbein, Thomas Michael Marti, Gregor Jan Kocher, Ralph A Schmid, Patrick Dorn, Ren-Wang Peng
MEK1 drives oncogenic signaling and interacts with PARP1 for genomic and metabolic homeostasis in malignant pleural mesothelioma. Cell death discovery 9 (1) (2023)
Haitang Yang, Yanyun Gao, Duo Xu, Ke Xu, Shun-Qing Liang, Zhang Yang, Amina Scherz, Sean R R Hall, Stefan Forster, Sabina A Berezowska, Feng Yao, Adrian F Ochsenbein, Thomas Michael Marti, Gregor Jan Kocher, Ralph A Schmid, Patrick Dorn, Ren-Wang Peng
MEK1 drives oncogenic signaling and interacts with PARP1 for genomic and metabolic homeostasis in malignant pleural mesothelioma. Cell death discovery 9 (1) (2023)
Haitang Yang, Yanyun Gao, Duo Xu, Ke Xu, Shun-Qing Liang, Zhang Yang, Amina Scherz, Sean R R Hall, Stefan Forster, Sabina A Berezowska, Feng Yao, Adrian F Ochsenbein, Thomas Michael Marti, Gregor Jan Kocher, Ralph A Schmid, Patrick Dorn, Ren-Wang Peng
MEK1 drives oncogenic signaling and interacts with PARP1 for genomic and metabolic homeostasis in malignant pleural mesothelioma. Cell death discovery 9 (1) (2023)
Darya Karatkevich, Haibin Deng, Yanyun Gao, Emilio Flint, Ren-Wang Peng, Ralph Alexander Schmid, Patrick Dorn, Thomas Michael Marti
Schedule-Dependent Treatment Increases Chemotherapy Efficacy in Malignant Pleural Mesothelioma. International journal of molecular sciences 23 (19) (2022)
Yanyun Gao, Marianna Kruithof de Julio, Ren-Wang Peng, Patrick Dorn
Organoids as a Model for Precision Medicine in Malignant Pleural Mesothelioma: Where Are We Today? Cancers 14 (15) (2022)
Duo Xu, Shengchen Liu, Xi Wu, Thomas Michael Marti, Patrick Dorn, Ralph A Schmid, Ren-Wang Peng, Yongqian Shu
Dissecting the Immunological Profiles in NSD3 -Amplified LUSC through Integrative Multi-Scale Analyses. Cancers 14 (20) (2022)
Wenjuan Ning, Zhang Yang, Gregor Jan Kocher, Patrick Dorn, Ren-Wang Peng
A Breakthrough Brought about by Targeting KRAS G12C : Nonconformity Is Punished. Cancers 14 (2) (2022)
Zhang Yang, Shun-Qing Liang, Liang Zhao, Haitang Yang, Thomas M Marti, Balazs Hegedüs, Yanyun Gao, Bin Zheng, Chun Chen, Wenxiang Wang, Patrick Dorn, Gregor J Kocher, Ralph A Schmid, Ren-Wang Peng
Metabolic synthetic lethality by targeting NOP56 and mTOR in KRAS-mutant lung cancer. Journal of experimental & clinical cancer research : CR 41 (1) (2022)
Haitang Yang, Sean R R Hall, Beibei Sun, Liang Zhao, Yanyun Gao, Ralph A Schmid, Swee T Tan, Ren-Wang Peng, Feng Yao
NF2 and Canonical Hippo-YAP Pathway Define Distinct Tumor Subsets Characterized by Different Immune Deficiency and Treatment Implications in Human Pleural Mesothelioma. Cancers 13 (7) (2021)
Zhang Yang, Shun-Qing Liang, Maria Saliakoura, Haitang Yang, Eric Vassella, Georgia Konstantinidou, Mario P Tschan, Balazs Hegedüs, Liang Zhao, Yanyun Gao, Duo Xu, Haibin Deng, Thomas M Marti, Gregor Jan Kocher, Wenxiang Wang, Ralph A Schmid, Ren-Wang Peng
Synergistic effects of FGFR1 and PLK1 inhibitors target a metabolic liability in KRAS-mutant cancer. EMBO molecular medicine 13 (9) (2021)
Zhang Yang, Shun-Qing Liang, Haitang Yang, Duo Xu, Remy Bruggmann, Yanyun Gao, Haibin Deng, Sabina A Berezowska, Sean R R Hall, Thomas Michael Marti, Gregor Jan Kocher, Qinghua Zhou, Ralph A Schmid, Ren-Wang Peng
CRISPR-Mediated Kinome Editing Prioritizes a Synergistic Combination Therapy for FGFR1-Amplified Lung Cancer. Cancer research 81 (11) (2021)
Duo Xu, Shun-Qing Liang, Zhang Yang, Haitang Yang, Remy Bruggmann, Simone Oberhaensli, Sabina A Berezowska, Thomas M Marti, Sean R R Hall, Patrick Dorn, Gregor J Kocher, Ralph A Schmid, Ren-Wang Peng
Malignant pleural mesothelioma co-opts BCL-XL and autophagy to escape apoptosis. Cell death & disease 12 (4) (2021)
Haitang Yang, Liang Zhao, Yanyun Gao, Feng Yao, Thomas Michael Marti, Ralph A Schmid, Ren-Wang Peng
Pharmacotranscriptomic Analysis Reveals Novel Drugs and Gene Networks Regulating Ferroptosis in Cancer. Cancers 12 (11) (2020)
Haitang Yang, Duo Xu, Ralph A Schmid, Ren-Wang Peng
Biomarker-guided targeted and immunotherapies in malignant pleural mesothelioma. Therapeutic advances in medical oncology 12 (2020)
Haitang Yang, Feng Yao, Thomas Michael Marti, Ralph A Schmid, Ren-Wang Peng
Beyond DNA Repair: DNA-PKcs in Tumor Metastasis, Metabolism and Immunity. Cancers 12 (11) (2020)
Matteo Rossi Sebastiano, Chiara Pozzato, Maria Saliakoura, Zhang Yang, Ren-Wang Peng, Mirco Galiè, Kevin Oberson, Hans-Uwe Simon, Evanthia Karamitopoulou, Georgia Konstantinidou
ACSL3-PAI-1 signaling axis mediates tumor-stroma cross-talk promoting pancreatic cancer progression. Science advances 6 (44) (2020)